- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00565669
Evaluation of Blink Tears and Systane Concomitant With Restasis for the Treatment of Dry Eye Symptoms
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Dry eye is a chronic condition that is believed to afflict more than 3 million patients in the United States.1 Symptoms of dry eye are very bothersome and impact quality of life, reduce work capacity, and may result in poorer psychological health. Also, symptoms of dry eye are associated with a decreased ability to perform activities that require visual attention such as reading and driving a car.2 Patients with dry eye complain most frequently of a scratchy or sandy (foreign body) sensation. Other common symptoms are itching, excessive mucus secretion, inability to produce tears, a burning sensation, photosensitivity, redness, pain, and difficulty in moving the lids. In most patients, the most remarkable feature of the eye examination is the grossly normal appearance of the eye.3 Chronic dry eye disease is associated with an inflammatory mechanism mediated by activated T-cell lymphocytes3 which affects the ocular surface and lacrimal gland.4 The damage caused by dry eye disease may be irreversible, and despite the availability of various tear substitutes, many patients with dry eye syndrome experience corneal injuries with a subsequent reduction in vision.5 Cyclosporin A (Restasis®, Allergan, Irvine, CA) has been shown to significantly reduce the number of activated T-lymphocytes within the conjunctiva6, thereby minimizing the inflammation causing dry eye. Topical cyclosporin A 0.05% ophthalmic emulsion (Restasis®, Allergan, Irvine, CA) increases tear production and improves the quality of naturally produced tears and is the first approved therapeutic agent for the treatment of chronic dry eye and the only treatment modality that addresses the underlying pathology.
In addition to topical therapy with cyclosporine, some patients continue to use artificial tears for occasional relief of residual symptoms. The choice of concomitant tear is important but little research has been published differentiating between the efficacy of these solutions when used concomitantly with topical cyclosporine.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina, Storm Eye Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject must have dry eye.
- Age: 18 years and older.
- Males or females
- Up to grade 3 conjunctival staining.
- Score of no more than 4 on the Subjective Evaluation of Symptoms of Dryness (SESOD) at screening.
- Currently using Restasis to treat dry eye syndrome (at least for 3 months prior to enrollment).
- Willing and able to comply with scheduled visits and other study procedures.
Exclusion Criteria:
- Prior unsuccessful use of topical cyclosporine (defined as patients taking it at least 3 months without improvement.
- Known contraindications to any study medication or ingredients.
- Planned use of contact lenses (unless discontinued use more than 30 days prior to randomization.
- Contact lens use during the active treatment portion of the trial.
- Active ocular allergies.
- Ocular surgery within the past 3 months.
- Any concurrent infectious/non infectious conjunctivitis, keratitis or uveitis.
- Active ocular diseases or uncontrolled systemic disease (blepharitis patients that are actively being treated or disease that is uncontrollable.
- Pregnant or nursing mothers and females of childbearing potential not practicing a reliable and medically acceptable method of birth control.
- Participation in (or current participation) any investigational drug or device trial.
- Conjuctival staining grade 4.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Systane
|
systane to be used twice a day
|
Experimental: Blink Tears
|
blink tears to be used twice a day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Schirmer's Scores
Time Frame: baseline to 3 months
|
The Schirmer score is a score on a scale - minimum is 0 and the highest is 35 mm.
Above 15 mm is normal and less than 5 is severe dry eyes.
A positive score means there was an improvement, 0 will be no change from baseline and a negative one that there was a decreased in tears.
This change was calculated by subtracting the baseline value from the 3 months value (3 mo Schirmer's - baseline Schirmer's = amount of change).
|
baseline to 3 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Kerry D. Solomon, MD, Medical University of South Carolina, Storm Eye Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Lacrimal Apparatus Diseases
- Keratoconjunctivitis
- Conjunctivitis
- Conjunctival Diseases
- Keratitis
- Corneal Diseases
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Antifungal Agents
- Calcineurin Inhibitors
- Cyclosporine
- Cyclosporins
Other Study ID Numbers
- SEI-07-003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye Syndrome
-
Olympic Ophthalmics, Inc.RecruitingMicroBlepharoexfoliation, NuLids, iTEAR100, iLIDS100, Blepharitis, Dry Eye SyndromeUnited States
-
Fidia Farmaceutici s.p.a.RecruitingDry Eye Syndrome (DES)Italy
-
Instituto Universitario de Oftalmobiología Aplicada...Completed
-
Santen SASCompletedModerate to Severe Dry Eye SyndromeFrance
-
Senju Pharmaceutical Co., Ltd.CompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
ReGenTree, LLCCompletedDry Eye | Dry Eye SyndromesUnited States
-
AllerganCompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Applied Science & Performance InstituteTrue Eye Experts - New Tampa; True Eye Experts - Lutz; True Eye Experts - South...CompletedDry Eye | Dry Eye SyndromesUnited States
-
University of Alabama at BirminghamCompletedContact Lens Wearers With Dry Eye SyndromeUnited States
-
SIFI SpACompleted
Clinical Trials on Cyclosporin A Restasis®
-
Farwaniya HospitalCompletedManagement of Punctal StenosisKuwait
-
Julian M. Mackay-WigganAllerganCompleted
-
Baylor College of MedicineAllerganTerminatedDry EyeUnited States
-
Institute of Hematology & Blood Diseases HospitalUnknownUrination Disorders | Thrombosis | Proteinuria | Anemia, Hemolytic | Hemoglobinuria, Paroxysmal | Hemoglobinuria | Paroxysmal Nocturnal Hemoglobinuria | Bone Marrow Failure | Aplastic Anemia,China
-
Institute of Hematology & Blood Diseases HospitalUnknownUrination Disorders | Thrombosis | Proteinuria | Anemia, Hemolytic | Hemoglobinuria, Paroxysmal | Hemoglobinuria | Paroxysmal Nocturnal Hemoglobinuria | Bone Marrow Failure | Aplastic Anemia,China
-
Shandong UniversityNational Natural Science Foundation of ChinaUnknown
-
Johns Hopkins UniversityCompletedAtopic KeratoconjunctivitisUnited States
-
Coopervision, Inc.CompletedAmetropiaUnited States
-
Aurinia Pharmaceuticals Inc.Completed
-
Safaa AA KhaledAssiut UniversityCompletedAplastic AnemiaEgypt